Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

InfluenzaInfluenza Vaccines

Phase 2

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

CompletedNCT00719043

GlaxoSmithKlineInfluenza

Start: 2008-07-11End: 2011-02-18Updated: 2018-07-09

Phase 3

Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

CompletedNCT01788228

GlaxoSmithKlineInfluenza, Influenza Vaccines

Start: 2013-03-22End: 2015-02-25Updated: 2020-06-23

Related Papers

Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study

Health and Quality of Life Outcomes2019-05-069 citations